contraindications for glp 1 agonists include Frontiers Incidence of hematologic malignancies

contraindications for glp 1 agonists include Frontiers Incidence of hematologic malignancies

Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records - eClinicalMedicine

The mechanism of action of the DPP-4 inhibitors raises the question: Will these agents be effective in patients who have had diabetes for 10 to 15 years and who may no longer have any beta-cell function

The industry perspective partly aligns here: manufacturers want labels that fairly represent risk without undue alarm